利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

14 条记录 (耗时 0.038 秒)

    Glucagon/GLP-1 receptor co-agonists
    2.
    发明授权
    Glucagon/GLP-1 receptor co-agonists 有权
    胰高血糖素/ GLP-1受体共激动剂

    公开(公告)号：US08454971B2

    公开(公告)日：2013-06-04

    申请号：US12527140

    申请日：2008-02-13

    申请人： Jonathan Day ,  James Patterson ,  Joseph Chabenne ,  Maria Dimarchi ,  David L. Smiley ,  Richard D. Dimarchi

    发明人： Jonathan Day ,  James Patterson ,  Joseph Chabenne ,  Maria Dimarchi ,  David L. Smiley ,  Richard D. Dimarchi

    IPC分类号： A61K38/26 ,  C07K14/605

    CPC分类号： C07K14/605 ,  A61K38/00 ,  A61K38/26 ,  A61K47/60 ,  C07K16/00 ,  C07K2317/52 ,  C07K2319/30

    摘要： Modified glucagon peptides are disclosed having enhanced potency at the glucagon receptor relative to native glucagon. Further modification of the glucagon peptides by forming lactam bridges or the substitution of the terminal carboxylic acid with an amide group produces peptides exhibiting glucagon/GLP-1 receptor co-agonist activity. The solubility and stability of these high potency glucagon analogs can be further improved by modification of the polypeptides by pegylation, substitution of carboxy terminal amino acids, or the addition of a carboxy terminal peptide selected from the group consisting of SEQ ID NO: 26 (GPSSGAPPPS), SEQ ID NO: 27 (K-RNRNNIA) and SEQ ID NO: 28 (KRNR).

    摘要翻译： 公开了相对于天然胰高血糖素在胰高血糖素受体上具有增强的效力的改良的胰高血糖素肽。 通过形成内酰胺桥或用酰胺基取代末端羧酸对胰高血糖素肽进一步修饰产生显示胰高血糖素/ GLP-1受体共激动剂活性的肽。 这些高效胰高血糖素类似物的溶解度和稳定性可以通过聚乙二醇化，多肽羧基末端氨基酸的取代或加入选自SEQ ID NO：26（GPSSGAPPPS ），SEQ ID NO：27（K-RNRNNIA）和SEQ ID NO：28（KRNR）。

    GLUCAGON/GLP-1 RECEPTOR CO-AGONISTS
    3.
    发明申请
    GLUCAGON/GLP-1 RECEPTOR CO-AGONISTS 有权
    GLUCAGON / GLP-1受体协同作用

    公开(公告)号：US20110257092A1

    公开(公告)日：2011-10-20

    申请号：US12999283

    申请日：2009-06-16

    申请人： Richard D. Dimarchi ,  David l. Smiley ,  Maria Dimarchi ,  Joseph Chabenne ,  Jonathan Day ,  James Patterson ,  Brian Ward

    发明人： Richard D. Dimarchi ,  David l. Smiley ,  Maria Dimarchi ,  Joseph Chabenne ,  Jonathan Day ,  James Patterson ,  Brian Ward

    IPC分类号： A61K38/26 ,  A61P3/04 ,  A61P3/10 ,  C07K14/605

    CPC分类号： C07K14/605

    摘要： Modified glucagon peptides are disclosed having enhanced potency at the glucagon receptor relative to native glucagon. Further modification of the glucagon peptides by forming intramolecular bridges or the substitution of the terminal carboxylic acid with an amide group produces peptides exhibiting glucagon/GLP-1 receptor co-agonist activity. The solubility and stability of these high potency glucagon analogs can be further improved by modification of the polypeptides by pegylation, acylation, alkylation, substitution of carboxy terminal amino acids, C-terminal truncation, or the addition of a carboxy terminal peptide selected from the group consisting of SEQ ID NO: 26 (GPSSGAPPPS), SEQ ID NO: 27 (KRNRNNIA) and SEQ ID NO: 28 (KRNR).

    摘要翻译： 公开了相对于天然胰高血糖素在胰高血糖素受体上具有增强的效力的改良的胰高血糖素肽。 通过形成分子内桥或通过酰胺基取代末端羧酸对胰高血糖素肽进一步修饰产生显示胰高血糖素/ GLP-1受体共激动剂活性的肽。 通过聚乙二醇化，酰化，烷基化，羧基末端氨基酸的取代，C-末端截短或加入选自下组的羧基末端肽，可以进一步改善这些高效胰高血糖素类似物的溶解度和稳定性 由SEQ ID NO：26（GPSSGAPPPS），SEQ ID NO：27（KRNRNNIA）和SEQ ID NO：28（KRNR）组成。

    GLUCAGON ANALOGS EXHIBITING ENHANCED SOLUBILITY AND STABILITY IN PHYSIOLOGICAL pH BUFFERS
    5.
    发明申请
    GLUCAGON ANALOGS EXHIBITING ENHANCED SOLUBILITY AND STABILITY IN PHYSIOLOGICAL pH BUFFERS 有权
    GLUCAGON ANALOGS展示增强的生理pH缓冲液中的溶解性和稳定性

    公开(公告)号：US20110190200A1

    公开(公告)日：2011-08-04

    申请号：US12999284

    申请日：2009-06-16

    申请人： Richard D. DiMarchi ,  David L. Smiley ,  Maria Dimarchi ,  Joseph Chabenne ,  Jonathan Day

    发明人： Richard D. DiMarchi ,  David L. Smiley ,  Maria Dimarchi ,  Joseph Chabenne ,  Jonathan Day

    IPC分类号： A61K38/26 ,  C07K14/605 ,  A61P3/08

    CPC分类号： C07K14/605 ,  A61K38/00

    摘要： Modified glucagon peptides are disclosed having improved solubility and/or half-life while retaining glucagon agonist activity. The glycogen peptides have been modified by substitution of native amino acids with, and/or addition of, charged amino acids to the carboxy terminus of the peptide. The modified glucagon agonists can be further modified by pegylation, or the addition of a carboxy terminal peptide selected from the group consisting of SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 23, or both to further enhance the solubility of the glucagon agonist analogs.

    摘要翻译： 公开了具有改善的溶解度和/或半衰期同时保留胰高血糖素激动剂活性的改良的胰高血糖素肽。 糖原肽已经通过用带氨基酸的氨基酸取代天然氨基酸和/或添加到肽的羧基末端而被修饰。 修饰的胰高血糖素激动剂可以通过聚乙二醇化，或加入选自SEQ ID NO：20，SEQ ID NO：21，SEQ ID NO：23或两者的羧基末端肽进一步修饰，以进一步增强溶解度 的胰高血糖素激动剂类似物。

    Glucagon analogs exhibiting enhanced solubility and stability in physiological pH buffers
    6.
    发明授权
    Glucagon analogs exhibiting enhanced solubility and stability in physiological pH buffers 有权
    在生理pH缓冲液中表现出增强的溶解度和稳定性的胰高血糖素类似物

    公开(公告)号：US08450270B2

    公开(公告)日：2013-05-28

    申请号：US12999284

    申请日：2009-06-16

    申请人： Richard D. Dimarchi ,  David L. Smiley ,  Maria Dimarchi ,  Joseph Chabenne ,  Jonathan Day

    发明人： Richard D. Dimarchi ,  David L. Smiley ,  Maria Dimarchi ,  Joseph Chabenne ,  Jonathan Day

    IPC分类号： A61K35/00

    CPC分类号： C07K14/605 ,  A61K38/00

    摘要： Modified glucagon peptides are disclosed having improved solubility and/or half-life while retaining glucagon agonist activity. The glycogen peptides have been modified by substitution of native amino acids with, and/or addition of, charged amino acids to the carboxy terminus of the peptide. The modified glucagon agonists can be further modified by pegylation, or the addition of a carboxy terminal peptide selected from the group consisting of SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 23, or both to further enhance the solubility of the glucagon agonist analogs.

    摘要翻译： 公开了具有改善的溶解度和/或半衰期同时保留胰高血糖素激动剂活性的改良的胰高血糖素肽。 糖原肽已经通过用带氨基酸的氨基酸取代天然氨基酸和/或添加到肽的羧基末端而被修饰。 修饰的胰高血糖素激动剂可以通过聚乙二醇化，或加入选自SEQ ID NO：20，SEQ ID NO：21，SEQ ID NO：23或两者的羧基末端肽进一步修饰，以进一步增强溶解度 的胰高血糖素激动剂类似物。

    GLUCAGON/GLP-1 RECEPTOR CO-AGONISTS
    7.
    发明申请
    GLUCAGON/GLP-1 RECEPTOR CO-AGONISTS 有权
    GLUCAGON / GLP-1受体协同作用

    公开(公告)号：US20100190701A1

    公开(公告)日：2010-07-29

    申请号：US12527140

    申请日：2008-02-13

    申请人： Jonathan Day ,  James Patterson ,  Joseph Chabenne ,  Maria Dimarchi ,  David Smiely ,  Richard D. Dimarchi

    发明人： Jonathan Day ,  James Patterson ,  Joseph Chabenne ,  Maria Dimarchi ,  David Smiely ,  Richard D. Dimarchi

    IPC分类号： A61K38/26 ,  C07K14/605 ,  A61P3/10 ,  A61P3/04

    CPC分类号： C07K14/605 ,  A61K38/00 ,  A61K38/26 ,  A61K47/60 ,  C07K16/00 ,  C07K2317/52 ,  C07K2319/30

    摘要： Modified glucagon peptides are disclosed having enhanced potency at the glucagon receptor relative to native glucagon. Further modification of the glucagon peptides by forming lactam bridges or the substitution of the terminal carboxylic acid with an amide group produces peptides exhibiting glucagon/GLP-1 receptor co-agonist activity. The solubility and stability of these high potency glucagon analogs can be further improved by modification of the polypeptides by pegylation, substitution of carboxy terminal amino acids, or the addition of a carboxy terminal peptide selected from the group consisting of SEQ ID NO: 26 (GPSSGAPPPS), SEQ ID NO: 27 (K-RNRNNIA) and SEQ ID NO: 28 (KRNR).

    摘要翻译： 公开了相对于天然胰高血糖素在胰高血糖素受体上具有增强的效力的改良的胰高血糖素肽。 通过形成内酰胺桥或用酰胺基取代末端羧酸对胰高血糖素肽进一步修饰产生显示胰高血糖素/ GLP-1受体共激动剂活性的肽。 这些高效胰高血糖素类似物的溶解度和稳定性可以通过聚乙二醇化，多肽羧基末端氨基酸的取代或加入选自SEQ ID NO：26（GPSSGAPPPS ），SEQ ID NO：27（K-RNRNNIA）和SEQ ID NO：28（KRNR）。

    GLOVE WITH ANTI-ROLL DOWN/ANTI-RUCKING CUFF
    8.
    发明申请
    GLOVE WITH ANTI-ROLL DOWN/ANTI-RUCKING CUFF 审中-公开
    具有防倾倒/抗冲击功能的手套

    公开(公告)号：US20100050317A1

    公开(公告)日：2010-03-04

    申请号：US12532472

    申请日：2007-05-24

    申请人： Jonathan Day

    发明人： Jonathan Day

    IPC分类号： A41D13/12 ,  A41D19/00 ,  A41D19/02

    CPC分类号： A41D19/0089 ,  A61B42/00 ,  A61B42/10

    摘要： A glove comprises a hand portion and a wrist portion extending from the hand portion and terminates in a hand insertion opening. The wrist portion includes anti-roll down/anti-rucking means in the form of a band of friction enhancing material provided on a surface which, in use, will form the inside of the glove, whereby, in use, the friction enhancing portion contacts the sleeve of a garment worn by the user so as to increase friction against the wrist portion of the glove, thereby preventing roll-down/rucking of the glove. The friction enhancing material is applied prior to any finishing operation(s) which reduce(s) the residual tack of the glove material and is selected from a group of materials whose tack is substantially unaffected by the finishing operation.

    摘要翻译： 手套包括从手部延伸的手部和手腕部，并且终止于手插入口。 手腕部分包括设置在使用中将形成手套内部的表面上的摩擦增强材料带形式的防滚降/防倾倒装置，由此在使用中，摩擦增强部分接触 使用者佩戴的衣服的套筒，以增加与手套的手腕部分的摩擦力，从而防止手套的折叠/倒起。 摩擦增强材料在任何精整操作之前施加，其减少了手套材料的残留粘性，并且选自其粘性基本上不受整理操作影响的一组材料。

    Glucagon/GLP-1 receptor co-agonists
    9.
    发明授权
    Glucagon/GLP-1 receptor co-agonists 有权
    胰高血糖素/ GLP-1受体共激动剂

    公开(公告)号：US08969294B2

    公开(公告)日：2015-03-03

    申请号：US13567858

    申请日：2012-08-06

    申请人： Elisabetta Bianchi ,  Antonello Pessi ,  Jonathan Day ,  Richard Dimarchi ,  David Smiley

    发明人： Elisabetta Bianchi ,  Antonello Pessi ,  Jonathan Day ,  Richard Dimarchi ,  David Smiley

    IPC分类号： A61K38/26 ,  A61K38/12 ,  A61K38/00 ,  C07K14/605

    CPC分类号： C07K14/605

    摘要： Modified glucagon peptides are disclosed having enhanced potency at the glucagon receptor relative to native glucagon. Further modification of the glucagon peptides by forming intramolecular bridges or the substitution of the terminal carboxylic acid with an amide group produces peptides exhibiting glucagon/GLP-1 receptor co-agonist activity. The solubility and stability of these high potency glucagon analogs can be further improved by modification of the polypeptides by pegylation, acylation, alkylation, substitution of carboxy terminal amino acids, C-terminal truncation, or the addition of a carboxy terminal peptide selected from the group consisting of SEQ ID NO: 26 (GPSSGAPPPS), SEQ ID NO: 27 (KRNRNNIA) and SEQ ID NO: 28 (KRNR).

    摘要翻译： 公开了相对于天然胰高血糖素在胰高血糖素受体上具有增强的效力的改良的胰高血糖素肽。 通过形成分子内桥或通过酰胺基取代末端羧酸对胰高血糖素肽进一步修饰产生显示胰高血糖素/ GLP-1受体共激动剂活性的肽。 通过聚乙二醇化，酰化，烷基化，羧基末端氨基酸的取代，C-末端截短或加入选自下组的羧基末端肽，可以进一步改善这些高效胰高血糖素类似物的溶解度和稳定性 由SEQ ID NO：26（GPSSGAPPPS），SEQ ID NO：27（KRNRNNIA）和SEQ ID NO：28（KRNR）组成。

    Puncture And/Or Cut Resistant Glove Having Maximized Dexterity, Tactility, And Comfort
    10.
    发明申请
    Puncture And/Or Cut Resistant Glove Having Maximized Dexterity, Tactility, And Comfort 审中-公开
    穿刺和/或切割手套，最大限度地提高了敏捷性，触觉性和舒适性

    公开(公告)号：US20130139294A1

    公开(公告)日：2013-06-06

    申请号：US13639740

    申请日：2011-04-07

    申请人： Kathleen Zetune ,  Richard Dombrowski ,  Jonathan Day ,  Norman J. Wagner

    发明人： Kathleen Zetune ,  Richard Dombrowski ,  Jonathan Day ,  Norman J. Wagner

    IPC分类号： A41D19/015

    CPC分类号： A41D19/015 ,  A41D19/001 ,  A41D19/01505 ,  A61B42/00

    摘要： A glove or partial glove comprising a palmar portion and a dorsal portion comprising one or more finger/thumb extensions, the portions joined together at a sealed seam, the seam positioned such that the seam on each of the finger/thumb extensions is positioned adjacent the dorsal aspect of the user's finger/thumb with the palmar aspect extending over the fingertip in a hood-like configuration. The glove portions may comprise a shear-thickening-fluid (STF) treated textile base, including a multi-ply construction in which each ply comprises an STF-treated textile base. The glove may comprise an integral pathogen barrier, such as a coating that is impervious to blood and bloodborne pathogens, and may have one or more features that aids donning and/or provides an adjustable fit. The glove or partial glove may be a first glove in a glove system including at least a second, latex glove to be worn over the first glove.

    摘要翻译： 一种手套或部分手套，其包括手掌部分和背部部分，其包括一个或多个手指/拇指延伸部，所述部分在密封接缝处接合在一起，所述接缝被定位成使得每个手指/拇指延伸部上的接缝位于 使用者的手指/拇指的背部方面具有手指方式在罩状结构中延伸超过指尖。 手套部分可以包括经过剪切增稠液（STF）处理的织物基底，包括多层结构，其中每个层包括经STF处理的织物基底。 手套可以包含整体的病原体屏障，例如不透血液和血源性病原体的涂层，并且可以具有一个或多个有助于穿戴和/或提供可调配合的特征。 手套或部分手套可以是手套系统中的第一手套，其包括要穿在第一手套上的至少第二胶乳手套。